Tango Therapeutics, Inc.
TNGX Healthcare Biotechnology
Tango Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $62.4 million, up 48.3% from fiscal 2024.
- Revenue
- −100.0%
- EPS
- −5.71%
- Free cash flow
- −4.58%
Quarter to June 2026, against a year earlier
Follow TNGX
Alert me
Tango Therapeutics, Inc. (TNGX) Operating margin
Tango Therapeutics, Inc.'s operating margin over the twelve months to 30 June 2026 was 0.00%, up 178.4 percentage points from fiscal 2025 (−178.4%). Over the past ten years it has ranged from −681.8% (fiscal 2020) to −157.1% (fiscal 2021); the current reading is higher than 83% of that period. That is in line with the Biotechnology industry median of 0.00% and in line with the Healthcare sector median of 0.00%.
Operating margin, annual
Embed this chart
Annual newest first
| Period | Operating margin | Change (points) |
|---|---|---|
| FY2025 | −178.4% | 167.70 |
| FY2024 | −346.1% | (33.52) |
| FY2023 | −312.6% | 134.22 |
| FY2022 | −446.8% | (289.70) |
| FY2021 | −157.1% | 524.73 |
| FY2020 | −681.8% | — |
Quarterly newest first
| Period | Operating margin | Change (points) |
|---|---|---|
| Jun 2026 | 0.00% | 0.00 |
| Mar 2026 | 0.00% | 0.00 |
| Dec 2025 | 0.00% | (26.15) |
| Sep 2025 | 26.2% | 1,314.02 |
| 19 more quarters | Free account |
Against its own ten years
Operating margin against peers
| Company | Operating margin |
|---|---|
| ACAD ACADIA Pharmaceuticals Inc. compare | 10.2% |
| XENE Xenon Pharmaceuticals Inc. compare | 0.00% |
| IRON Disc Medicine, Inc. compare | 0.00% |
| EWTX Edgewise Therapeutics, Inc. compare | 0.00% |
| PBLS Parabilis Medicines, Inc. compare | 0.00% |
| TNGX Tango Therapeutics, Inc. | 0.00% |
| IOVA Iovance Biotherapeutics, Inc. compare | −60.8% |
| ABCL AbCellera Biologics Inc. compare | −340.3% |
| RLAY Relay Therapeutics, Inc. compare | −2,815.5% |
| Biotechnology industry median | 0.00% |
| Healthcare sector median | 0.00% |
| Market median | 0.00% |
What Operating margin is
EBIT Margin tells an investor how much operating profit, before interest and taxes, a company keeps from each unit of revenue.
EBIT ÷ Revenue
More on TNGX
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- The full statement